Handelsavisen
prelaunch
06
060280.KQ KOSDAQ Food Retail & Distribution

Curexo Inc

$13 000,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
534,2B KRW
P/E
EV / Rev
Div yield
Op margin
3,2 %
ROE
2,9 %
Net margin
3,7 %
Debt / equity
0,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Curexo Inc operates in the Food & Drug Retailing industry, generating revenue primarily through the retail and distribution of food and drug products.

Business. Curexo Inc (060280.KQ) is a food and drug retailing company listed on the KOSDAQ exchange. The firm operates within the Consumer Non-Cyclicals sector, specifically focusing on food retail and distribution activities. No specific operating segments or geographic breakdowns are provided in the available data. The company is headquartered in South Korea, consistent with its primary listing on the Korean exchange.

Classification92 %
SectorConsumer Non-Cyclicals
Business sectorFood & Drug Retailing
IndustryFood Retail & Distribution
ActivityFood & Drug Retailing
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
2,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 060280.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 060280.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Curexo Inc (060280.KQ) is a food and drug retailing company listed on the KOSDAQ exchange. The firm operates within the Consumer Non-Cyclicals sector, specifically focusing on food retail and distribution activities. No specific operating segments or geographic breakdowns are provided in the available data. The company is headquartered in South Korea, consistent with its primary listing on the Korean exchange.

    Classification92 %
    SectorConsumer Non-Cyclicals
    Business sectorFood & Drug Retailing
    IndustryFood Retail & Distribution
    ActivityFood & Drug Retailing
    AI synthesis
    GENERATED

    Curexo Inc maintains a strong liquidity position, with a current ratio of 20.69 and cash and equivalents amounting to 18,687,406,190 KRW, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing. Despite a negative operating cash flow of -11,258,378,660 KRW, the company's free cash flow of 3,043,336,520 KRW supports ongoing operations and potential reinvestment.

    Profitability metrics for Curexo Inc show a return on equity (ROE) of 2.88% and a return on assets (ROA) of 2.74%, which are below the industry median for the Food Retail & Distribution sector. The company's gross profit margin is 33.33%, and its operating margin is 3.17%, both of which are in line with the sector median. However, the company's net income of 2,771,488,550 KRW indicates a solid bottom-line performance.

    Curexo Inc's revenue is concentrated in the Food & Drug Retailing segment, with no disclosed geographic diversification. The company's revenue is primarily derived from a single business line, which may expose it to higher operational and market risks. The company's market share is not disclosed, but its revenue of 74,531,816,400 KRW suggests a significant presence in the industry.

    The company's growth trajectory is mixed. Analysts estimate a mean revenue of 241,066,670,000 KRW for the current fiscal year, representing a substantial increase from the last actual revenue of 74,545,000,000 KRW. However, the mean EPS estimate of 140.25 KRW is significantly higher than the last actual EPS of 67.00 KRW, indicating potential volatility in earnings. The company's capital expenditure of -2,513,503,320 KRW suggests a focus on cost management and efficiency.

    Risk factors for Curexo Inc include low liquidity and dilution risks, with no immediate filing-based flags detected. The company's low debt levels and strong equity position mitigate credit risk. However, the high price-to-earnings ratio of 192.74 and price-to-book ratio of 5.55 suggest that the stock may be overvalued relative to its fundamentals. The company's conservative capital structure and strong liquidity position reduce the likelihood of near-term dilution.

    Recent events and filings for Curexo Inc do not indicate any significant changes in the company's financial or operational status. The company's recent performance and analyst estimates suggest a potential for growth, but the high valuation multiples may pose a challenge for sustaining investor confidence.

    Key takeaways
    • Curexo Inc has a strong liquidity position with a current ratio of 20.69 and significant cash reserves.
    • The company's profitability metrics, including ROE and ROA, are below the industry median, indicating room for improvement.
    • Revenue is concentrated in a single segment, which may increase operational and market risks.
    • Analyst estimates suggest potential revenue and EPS growth, but the high valuation multiples may pose a challenge.
    • The company's conservative capital structure and low debt levels reduce credit and dilution risks.
    • "margin_outlook_rationale": "The company's gross profit margin is in line with the sector median, but the operating margin is below the median, indicating potential cost management challenges.",

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $13 000,00
    Market cap
    $534.17B
    Enterprise value
    $516.65B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    5.5x
    P / Tangible book
    5.5x
    Tangible book
    $96.25B
    Net cash
    $17.52B
    Current ratio
    20.7
    Debt / equity
    0.0
    ROA
    2.7%
    ROE
    2.9%
    Cash conversion
    -406.0%
    CapEx / revenue
    -3.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    140,25
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-20 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate140,25
    Revenueno estimateno estimate241,1B KRW
    Operating incomeno estimateno estimate6,2B KRW
    Full-year consensus mean (period as reported by source) · consensus in KRW. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Operating income · consensus6,2B KRW
    EPS surprise
    −52,2 %
    reported vs consensus · miss
    Revenue surprise
    −69,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin3,2 %Above median
    Net Margin3,7 %Above median
    ROE2,9 %Below median
    Capex / Rev-3,4 %Below median
    D/E0,01Above P75
    Cash Conv-4,06Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Curexo Inc Market data — financials · 2026-05-26
    • Curexo Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    060280.KQCanonical
    KOSDAQ · KRW

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage